Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3475 With Gemcitabine in Previously-Treated Advanced NSCLC
NCT02422381Phase 2Active, not recruiting
- Start
- Jul 2015
- Primary completion
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC). Started Jul 2015; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02422381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02422381.